Evidence map›Paper›PMID 26421979›Full record

ArticleGrowth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society2016

Growth hormone signaling pathways.

Christin Carter-Su, Jessica Schwartz, Lawrence S Argetsinger

Open access · greenAbstract read
In one paragraph

Article in Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
3.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 118 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. GHRH in diabetes and metabolism.Reviews in endocrine & metabolic disorders · 2025
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Growth hormone and nonalcoholic fatty liver disease.Immunometabolism (Cobham, Surrey) · 2023 · on this map
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Christin Carter-SuDepartments of Molecular and Integrative Physiology and of Internal Medicine, The University of Michigan Medical School, Ann Arbor, MI 48109, United States. Electronic address: cartersu@umich.edu.
Jessica SchwartzDepartments of Molecular and Integrative Physiology and of Internal Medicine, The University of Michigan Medical School, Ann Arbor, MI 48109, United States.
Lawrence S ArgetsingerDepartments of Molecular and Integrative Physiology and of Internal Medicine, The University of Michigan Medical School, Ann Arbor, MI 48109, United States.
University of Michigan–Ann Arbor · US

Funding

Growth Hormone Regulation of SH2B1R01DK054222 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CARTER-SU, CHRISTIN · 1999 to 2020
$7.7M
GROWTH HORMONE SIGNALING TO THE NUCLEUSR01DK046072 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SCHWARTZ, JESSICA · 1996 to 2010
$2.3M
NIDDK NIH HHS R01 DK046072NIDDK NIH HHS R01 DK054222
6 · The paper itself

Abstract

Over 20years ago, our laboratory showed that growth hormone (GH) signals through the GH receptor-associated tyrosine kinase JAK2. We showed that GH binding to its membrane-bound receptor enhances binding of JAK2 to the GHR, activates JAK2, and stimulates tyrosyl phosphorylation of both JAK2 and GHR. The activated JAK2/GHR complex recruits a variety of signaling proteins, thereby initiating multiple signaling pathways and cellular responses. These proteins and pathways include: 1) Stat transcription factors implicated in the expression of multiple genes, including the gene encoding insulin-like growth factor 1; 2) Shc adapter proteins that lead to activation of the grb2-SOS-Ras-Raf-MEK-ERK1,2 pathway; 3) insulin receptor substrate proteins implicated in the phosphatidylinositol-3-kinase and Akt pathway; 4) signal regulatory protein α, a transmembrane scaffold protein that recruits proteins including the tyrosine phosphatase SHP2; and 5) SH2B1, a scaffold protein that can activate JAK2 and enhance GH regulation of the actin cytoskeleton. Our recent work has focused on the function of SH2B1. We have shown that SH2B1β is recruited to and phosphorylated by JAK2 in response to GH. SH2B1 localizes to the plasma membrane, cytoplasm and focal adhesions; it also cycles through the nucleus. SH2B1 regulates the actin cytoskeleton and promotes GH-dependent motility of RAW264.7 macrophages. Mutations in SH2B1 have been found in humans exhibiting severe early-onset childhood obesity and insulin resistance. These mutations impair SH2B1 enhancement of GH-induced macrophage motility. As SH2B1 is expressed ubiquitously and is also recruited to a variety of receptor tyrosine kinases, our results raise the possibility that effects of SH2B1 on the actin cytoskeleton in various cell types, including neurons, may play a role in regulating body weight.

Indexed as

Actin CytoskeletonAdaptor Proteins, Signal TransducingAnimalsCell MovementGrowth HormoneHumansInsulin ResistanceJanus Kinase 2Mitogen-Activated Protein Kinase KinasesPediatric ObesityPhosphatidylinositol 3-KinasesPhosphorylationProto-Oncogene Proteins c-aktReceptors, SomatotropinSignal TransductionSTAT Transcription FactorsAdaptor Proteins, Signal TransducingGrowth HormoneJanus Kinase 2Mitogen-Activated Protein Kinase KinasesPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktReceptors, SomatotropinSH2B1 protein, humanSTAT Transcription FactorsGrowth hormoneJAK2SH2B1Signal transduction

Identifiers

PMID26421979
PMCPMC7644140
OpenAlexW1659717266

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.